List of Exservan drug patents
Exservan is owned by Mitsubishi Holdings.
Exservan contains Riluzole.
Exservan has a total of 2 drug patents out of which 0 drug patents have expired.
Exservan was authorised for market use on 22 November, 2019.
Exservan is available in film;oral dosage forms.
The generics of Exservan are possible to be released after 03 April, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | MITSUBISHI HOLDINGS | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(1 year, 17 days from now) | |
| US8603514 | MITSUBISHI HOLDINGS | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month from now) | |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 22 November, 2019
Treatment: NA
Dosage: FILM;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic